Therapeutic potential of acyclovir and of the interferons in HBV-related chronic active hepatitis due to HBV with or without HDV superinfection.
Acyclovir only demonstrated activity in CAH patients with low HBV replication (DNA-p less than or equal to 80 cpm). In those, oral acyclovir 4 g/day for 4 months was able to permanently inhibit DNA-p in 5/5 cases without significant side-effects.
D000212:Acyclovir / Q000627:therapeutic use*; D006509:Hepatitis B / Q000150:complications / Q000628:therapy*; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology; D003699:Hepatitis D / Q000150:complications*; D006521:Hepatitis, Chronic / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D014740:Vidarabine / Q000627:therapeutic use; D014779:Virus Replication / Q000187:drug effects
D007372:Interferons; D014740:Vidarabine; D000212:Acyclovir